Furthermore, DCs themselves could also infiltrated into the tumors indicating that IL-2 treatment could promote a sustained T cell immunity to pancreatic cancer not only by generating tumor specific T cells but also upregulating DCs infiltration. This evidence concerns the gene IL2 and familial pancreatic carcinoma.